The Development and Reform Commission will promote the reform of drug prices from four aspects

Source: on August 26, 2013, under the background that the main task of drug price supervision in the securities times is changing from "limiting the price and preventing inflation" to guiding the reasonable price formation and regulating the market price behavior, the relevant institutions of the national development and Reform Commission plan to promote the drug price reform from four aspects, and hope to achieve results in one year, especially at the policy-making level Song Dacai, director of the medicine price department of the price department of the national development and Reform Commission, said at the 2013 annual conference of Chinese medicine entrepreneurs held recently that since this century, the national development and Reform Commission has carried out three rounds of drug price adjustment, the third round since 2010 At present, the price adjustment of chemical drugs has ended, while the price adjustment of Chinese patent medicine is in progress So far, the national development and Reform Commission has organized 25 batches of professional cost surveys and investigated the ex factory prices of more than 1000 drugs At the same time, through online monitoring, the national development and Reform Commission has directly collected and mastered the ex factory prices of drugs, which has laid a solid foundation for price adjustment and formulation In Song Dacai's view, with the deepening of the operation of public hospitals and the reform of compensation mechanism, the current drug price management mechanism will gradually be broken, the hospital's awareness of standardizing its own drug use behavior and actively controlling cost will gradually increase, and the unreasonable "maintenance" of drug prices will be gradually eliminated The cost will be gradually reduced; the role of market mechanism in the formation of drug prices will be further played, and centralized bidding and procurement has become an important means to find prices through market competition, especially the implementation of new bidding and procurement mechanism for essential drugs, effectively reducing drug prices through market means At the same time, song Dacai stressed that there are still several main problems in the current drug price management, that is, although the maximum retail price limit has played a role in preventing inflation, it is out of line with the actual market; the drug bidding and purchasing system is not perfect, and it has not played the original effect, especially the goal of using competition mechanism to find a reasonable price has not been achieved; the relationship between drug price comparison is not good Reasonable, especially the price difference between some domestic and foreign enterprises is too large Based on the existing problems, song Dacai said that in the future, drug price reform will be promoted from four aspects The first is to explore a new form of price management with payment guidance price as the core To make the payment guidance price as the basis of medical insurance payment; to remove the maximum retail price limit and play the role of market competition; to stimulate the enthusiasm of medical institutions to reduce the drug purchase price In Song Dacai's view, the implementation of the payment guidance price is a means adopted by many countries, especially the countries with universal medical insurance On the one hand, the policy helps to gradually weaken the sensitivity of the masses to the drug price, and ensure that the burden of the insured patients does not increase and gradually decrease; on the other hand, it can promote the medical institutions to drive down the purchase price; on the other hand, it is also conducive to ensuring different consumption demands in the market On the premise of that, we should solve the problem that the price difference between domestic and foreign drugs is too large However, song Dacai stressed that at present, the conditions for the full implementation of the guiding price payment are not very mature It is planned to select some places to carry out the pilot and then select the opportunity for full implementation The second is to improve drug pricing methods, including the introduction of drug economic evaluation and international price comparison pricing methods, and some varieties can also be explored to negotiate pricing methods The third is to formulate price policies to encourage R & D and innovation, including the implementation of incentive policies for patent drugs and secret prescriptions from the perspective of intellectual property rights, the encouragement of winning national awards, exporting to the international mainstream market and first imitation from the perspective of industry, and the implementation of differentiated price policies for drugs with quality advantages and consistency evaluation from the perspective of quality control The fourth is to improve the price management of cheap drugs and use price leverage to encourage the production and supply of cheap drugs